Jeena Sikho Lifecare Past Earnings Performance
Past criteria checks 6/6
Jeena Sikho Lifecare has been growing earnings at an average annual rate of 46%, while the Healthcare industry saw earnings growing at 25.3% annually. Revenues have been growing at an average rate of 33.5% per year. Jeena Sikho Lifecare's return on equity is 47.5%, and it has net margins of 27.7%.
Key information
46.02%
Earnings growth rate
44.88%
EPS growth rate
| Healthcare Industry Growth | 29.41% |
| Revenue growth rate | 33.53% |
| Return on equity | 47.48% |
| Net Margin | 27.68% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 15
JSLL: Hospital Collaboration Will Support Future Upside Potential
Analysts have trimmed their price target for Jeena Sikho Lifecare from ₹1,200 to ₹1,000. This reflects updated assumptions for more moderate revenue growth, slightly lower profit margins and a modestly higher future P/E multiple.Analysis Article • Jun 02
Here's Why We Think Jeena Sikho Lifecare (NSE:JSLL) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Jun 01
JSLL: Hospital Collaboration And Land Monetisation Will Support Future Upside Potential
Analysts have kept the fair value for Jeena Sikho Lifecare steady at ₹1,200. The unchanged target reflects updated assumptions of slightly lower revenue growth, a modestly higher profit margin, and a reduced future P/E multiple in their models.Narrative Update • May 12
JSLL: Hospital Collaboration And Land Monetisation Will Support Future Upside Potential
Analysts have kept the fair value estimate for Jeena Sikho Lifecare steady at ₹1,200, with only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E. This reflects a broadly unchanged view on the stock's long term potential.Narrative Update • Apr 21
JSLL: Hospital Collaboration Framework Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Jeena Sikho Lifecare at ₹1,200, citing unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Jeena Sikho Lifecare signed a Memorandum of Understanding with Sat Kartar Life Limited on April 14, 2026, to explore collaboration that links Sat Kartar Life Limited’s data-driven patient acquisition ecosystem with Jeena Sikho Lifecare’s clinical and institutional healthcare network, with Jeena Sikho Lifecare retaining full control over diagnosis, treatment and healthcare delivery (Key Developments).Narrative Update • Apr 06
JSLL: Unchanged Fair Value Will Support Future Upside From Consistent Assumptions
Analysts have kept their fair value estimate for Jeena Sikho Lifecare steady at ₹1,200, pointing to largely unchanged assumptions for growth, margins and future P/E. This suggests their latest review supports the previous price target rather than calling for a revision.Analysis Article • Apr 06
What Does Jeena Sikho Lifecare Limited's (NSE:JSLL) Share Price Indicate?
Jeena Sikho Lifecare Limited ( NSE:JSLL ), might not be a large cap stock, but it saw a double-digit share price rise...Narrative Update • Mar 22
JSLL: Stable Governance And Steady Assumptions Will Support Future Upside Potential
Analysts have kept their price target for Jeena Sikho Lifecare steady at ₹1,200, citing unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the basis for this stance. What's in the News A board meeting is scheduled for Mar 09, 2026 to approve amendments to the Code of Fair Disclosure, internal procedures for regulating and monitoring trading by designated persons and their immediate relatives, and the Legitimate Purpose Policy (company filing).Narrative Update • Mar 07
JSLL: Stable Assumptions And Index Inclusion Will Support Future Upside Potential
Analysts have kept their fair value estimate for Jeena Sikho Lifecare steady at ₹1,200, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for maintaining the current price target. What's in the News Board meeting scheduled on Feb 7, 2026 to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the limited review report, and to take up any other business with the chairperson's approval (Key Developments).Narrative Update • Feb 20
JSLL: Higher Margin Outlook Will Support Future Upside Potential
Analysts have lifted their price target for Jeena Sikho Lifecare from ₹950 to ₹1,200, citing updated assumptions for revenue growth, higher profit margins, and a lower future P/E multiple in their refreshed valuation model. What's in the News A board meeting is scheduled on Feb 7, 2026 to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the limited review report, and to consider other items with the chairperson's approval (company filing).Analysis Article • Feb 12
Rainbows and Unicorns: The Jeena Sikho Lifecare Limited (NSE:JSLL) Analyst Just Became A Lot More Optimistic
Shareholders in Jeena Sikho Lifecare Limited ( NSE:JSLL ) may be thrilled to learn that the covering analyst has just...Narrative Update • Feb 06
JSLL: Subsidiary Loan And Index Inclusion Will Support Future Upside
Analysts have maintained their fair value estimate for Jeena Sikho Lifecare at ₹950.00 per share, making small tweaks to the discount rate and future P/E assumptions to reflect updated views on the company’s risk profile and earnings quality. What's in the News A board meeting is scheduled for Feb 7, 2026 to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the limited review report, and to consider other items with the chairperson's approval (company filing).Analysis Article • Feb 05
Is Now The Time To Put Jeena Sikho Lifecare (NSE:JSLL) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Jan 22
JSLL: Subsidiary Loan And Index Inclusion Will Support Future Upside
Analysts have kept the fair value estimate for Jeena Sikho Lifecare steady at ₹950.00, explaining that slightly softer revenue growth and profit margin assumptions are broadly offset by a higher future P/E multiple of 35.08x versus the earlier 32.68x. What's in the News Board meeting scheduled on Jan 21, 2026 at 17:30 IST to consider executing a loan agreement with wholly owned subsidiary Jeena Sikho International LLC for an unsecured loan of AED 7.53 million, planned in two tranches on an arm's length basis (company filing).Narrative Update • Jan 07
JSLL: Exclusive Diagnostics Alliance Will Support Future Hospital Network Upside
Analysts have maintained their fair value estimate for Jeena Sikho Lifecare at ₹950 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a revision at this time. What's in the News Jeena Sikho Lifecare plans a board meeting on December 23, 2025, at 19:00 Indian Standard Time to consider the resignation of M/s Deepak K Garg & Associates as internal auditor and the potential appointment of M/s Forvis Mazars LLP as the new internal auditor (company filing).Analysis Article • Dec 18
At ₹745, Is Jeena Sikho Lifecare Limited (NSE:JSLL) Worth Looking At Closely?
Jeena Sikho Lifecare Limited ( NSE:JSLL ), might not be a large cap stock, but it saw a decent share price growth of...Narrative Update • Dec 17
JSLL: New Diagnostics Alliance Will Drive Hospital Network Expansion And Upside
Analysts have maintained their Jeena Sikho Lifecare price target at ₹950.00, reflecting continued confidence in the company’s revenue growth outlook, resilient profit margins, and forward valuation multiples. What's in the News Board meeting scheduled on November 6, 2025 to consider and approve unaudited financial results for the quarter ended September 30, 2025, along with the limited review report and other matters with the chairperson's approval (company filing) National launch of the Pet Yakrit Pleeha Shuddhi Kit under the Pet Shuddhi product line, expanding availability across India through the Jeena Sikho Hospitals Network and targeting detoxification and digestive wellness (company event) Exclusive five year diagnostic collaboration agreement signed with Chandan Healthcare Limited, making Chandan the official diagnostics partner across all current and future Jeena Sikho hospitals, clinics and wellness centers (board decision) Shareholders approved a final dividend of INR 1.10 per equity share of face value INR 2 for FY 2024 25 at the AGM held on September 29, 2025 (AGM resolution) Appointment of M/s Walker Chandiok and Co LLP as statutory auditor to fill a casual vacancy, approved at the September 29, 2025 AGM (AGM resolution) Valuation Changes Fair Value: unchanged at ₹950.00 per share, indicating no revision to the intrinsic value estimate.Narrative Update • Dec 03
JSLL: New Diagnostic Alliance Will Drive Network Expansion And Long Term Upside
Analysts have nudged their price target on Jeena Sikho Lifecare slightly higher to align with an updated fair value estimate of ₹950.00, reflecting confidence in the company’s projected revenue growth and stable profit margins. What's in the News A board meeting is scheduled on November 6, 2025, to review and approve unaudited financial results for the quarter ended September 30, 2025, and to address other business with the chairperson's approval (company filing).Narrative Update • Nov 19
JSLL: Exclusive Diagnostic Partnership Will Drive Expansion Into New Markets
Analysts have raised their price target for Jeena Sikho Lifecare from ₹900 to ₹950. They cite a modest improvement in projected revenue growth and a lower expected future price-earnings ratio as supporting factors for the upward revision.Analysis Article • Nov 05
With EPS Growth And More, Jeena Sikho Lifecare (NSE:JSLL) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...New Narrative • Aug 10
Rising Health Awareness And AYUSH Trends Will Drive Global Expansion
Expanding in-house manufacturing and proprietary products improves cost control, margins, and earnings resilience as the company scales across markets.Analysis Article • Jul 13
Investors Appear Satisfied With Jeena Sikho Lifecare Limited's (NSE:JSLL) Prospects As Shares Rocket 29%
Jeena Sikho Lifecare Limited ( NSE:JSLL ) shares have had a really impressive month, gaining 29% after a shaky period...Analysis Article • Jul 02
Does Jeena Sikho Lifecare (NSE:JSLL) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Jun 02
Jeena Sikho Lifecare (NSE:JSLL) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off Jeena Sikho Lifecare Limited's ( NSE:JSLL ) solid earnings report. We think that investors...Analysis Article • Feb 25
If EPS Growth Is Important To You, Jeena Sikho Lifecare (NSE:JSLL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Nov 23
Investors Shouldn't Be Too Comfortable With Jeena Sikho Lifecare's (NSE:JSLL) Earnings
Jeena Sikho Lifecare Limited ( NSE:JSLL ) just reported some strong earnings, and the market reacted accordingly with a...Analysis Article • Aug 20
Why Investors Shouldn't Be Surprised By Jeena Sikho Lifecare Limited's (NSE:JSLL) 31% Share Price Surge
Jeena Sikho Lifecare Limited ( NSE:JSLL ) shareholders would be excited to see that the share price has had a great...Analysis Article • Aug 01
Jeena Sikho Lifecare (NSE:JSLL) Will Pay A Larger Dividend Than Last Year At ₹4.18
Jeena Sikho Lifecare Limited ( NSE:JSLL ) has announced that it will be increasing its dividend from last year's...Analysis Article • May 24
Jeena Sikho Lifecare's (NSE:JSLL) Earnings Are Weaker Than They Seem
Jeena Sikho Lifecare Limited ( NSE:JSLL ) announced strong profits, but the stock was stagnant. We did some digging...Analysis Article • Apr 03
Should You Be Adding Jeena Sikho Lifecare (NSE:JSLL) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Feb 08
With Jeena Sikho Lifecare Limited (NSE:JSLL) It Looks Like You'll Get What You Pay For
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 32x, you may consider Jeena...Analysis Article • Nov 01
Here's Why We Think Jeena Sikho Lifecare (NSE:JSLL) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Jul 15
With EPS Growth And More, Jeena Sikho Lifecare (NSE:JSLL) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Nov 18
Jeena Sikho Lifecare Limited's (NSE:JSLL) Shares Climb 41% But Its Business Is Yet to Catch Up
Jeena Sikho Lifecare Limited ( NSE:JSLL ) shareholders have had their patience rewarded with a 41% share price jump in...Analysis Article • Aug 02
Jeena Sikho Lifecare's (NSE:JSLL) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Jeena Sikho Lifecare Limited's ( NSE:JSLL ) stock hasn't moved...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Jeena Sikho Lifecare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 8,014 | 2,219 | 1,484 | 0 |
| 31 Dec 25 | 7,251 | 2,128 | 2,208 | 0 |
| 30 Sep 25 | 6,191 | 1,584 | 2,082 | 0 |
| 30 Jun 25 | 5,363 | 1,186 | 1,078 | 0 |
| 31 Mar 25 | 4,691 | 907 | 1,903 | 0 |
| 31 Dec 24 | 4,133 | 733 | 1,198 | 0 |
| 30 Sep 24 | 3,812 | 843 | 1,409 | 0 |
| 30 Jun 24 | 3,528 | 767 | 1,335 | 0 |
| 31 Mar 24 | 3,244 | 692 | 1,262 | 0 |
| 31 Dec 23 | 2,989 | 618 | 1,077 | 0 |
| 30 Sep 23 | 2,752 | 545 | 903 | 0 |
| 30 Jun 23 | 2,400 | 442 | 850 | 0 |
| 31 Mar 23 | 2,039 | 337 | 791 | 0 |
| 31 Mar 22 | 1,466 | 112 | 706 | 0 |
| 31 Mar 21 | 1,358 | 102 | 650 | 0 |
| 31 Mar 20 | 944 | 57 | 216 | 0 |
| 31 Mar 19 | 1,058 | 60 | 144 | 0 |
Quality Earnings: JSLL has high quality earnings.
Growing Profit Margin: JSLL's current net profit margins (27.7%) are higher than last year (19.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JSLL's earnings have grown significantly by 46% per year over the past 5 years.
Accelerating Growth: JSLL's earnings growth over the past year (144.5%) exceeds its 5-year average (46% per year).
Earnings vs Industry: JSLL earnings growth over the past year (144.5%) exceeded the Healthcare industry 21%.
Return on Equity
High ROE: JSLL's Return on Equity (47.5%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 19:33 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jeena Sikho Lifecare Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Deepika Murarka | Choice Equity Broking Private Limited |